Across TCGA pan-cancer cohorts, TXNIP Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TXNIP data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher TXNIP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TXNIP expression acts as an unfavorable survival marker.
THYM, BLCA, and LUSC are the cancer types where TXNIP Mutation most reproducibly stratifies survival.